FDA Panel Votes To Lift Peptide Ban—Panel Members Stand To Profit
NEWS & RESEARCH
In July 2026, the Pharmacy Compounding Advisory Committee of the Food and Drug Administration (FDA) voted to recommend lifting restrictions on six experimental peptides that have been banned since 2023 over safety concerns. Just weeks before the vote, Health and Human Service Secretary Robert F. Kennedy Jr., a self-described "big fan" of peptides who has long pushed for their deregulation, seated eight new members on the panel, six of whom "run peptide clinics, sell peptide injections, or promote the substances online," meaning they stand to profit directly from the products they were asked to evaluate. Peptides, which have become trendy in recent years on social media, are chains of amino acids that occur naturally in the body but can also be made synthetically in laboratories. Influencers have credited them with everything from weight loss and muscle growth to glowing skin and slowed aging. However, FDA's own scientists urged the panel to reject all the peptides under review, citing insufficient data on safety and effectiveness, as several had never been tested on human subjects. The committee ignored them. Its votes are non-binding, and any change would first have to be published as a proposed rule open to public comment—but the FDA usually follows its advisory panels.
SOURCES: New York Times | NBC | NPR | Forbes | US News
ANALYSIS & OPINION
Most of the peptides under review have not been studied outside of rodents or a petri dish, so there is no evidence about their effects on humans, including long-term. However, the limited amount of non-human research raises major health concerns, suggesting these compounds could enhance tumor growth, cause immune reactions, and raise cancer risk with prolonged exposure. In fact, one of the peptides that the panel approved, TB-500, was initially developed as a veterinary drug to boost performance in horse and greyhound racing. Public health advocates maintain that rigorous, large-scale human clinical trials are needed before the FDA should allow pharmacies to produce these peptides for patients. As Dr. Eric Topol, founder of the Scripps Research Translational Institute, said, "I don't have a bias that the peptides are bad, necessarily. I just want to see the evidence, and we don't have any." Beyond the scientific worries, there are also concerns about the integrity of the meeting itself, as six of the eight members Kennedy seated are tied to the peptide industry. Dr. Peter Lurie, president of the Center for Science in the Public Interest and a former FDA official, argues that a "reputable panel typically would exclude members with a financial interest in the outcome of a vote." He has called the proceeding an "extraordinary abuse of the advisory committee process to secure ends that have no basis in science."
SOURCES: New York Times | NBC | NPR | Forbes | US News
HOW TO FIX IT
Federal action:
Reintroduce and pass the Hinchey Amendment, closing the gap it left open. In 2006 the House voted to bar the FDA from spending federal money to grant conflict-of-interest waivers to advisory committee members, but it never became permanent law. Reviving it alone wouldn't have stopped this panel, because no waivers appear to have been issued—none were needed. Federal ethics rules (5 CFR § 2640.203(g)) automatically let an adviser vote on a decision that benefits an entire industry rather than a single company, which is exactly what deregulating peptides does. Congress would have to narrow that exemption, so that a member is disqualified when they or their employer make money selling the product under review.
Pass legislation codifying a reasoned-explanation standard when FDA departs from its own scientific staff. Require the FDA to publish a point-by-point justification in the Federal Register when a final decision contradicts its career reviewers, and make that justification reviewable under the Administrative Procedure Act.
Require actual scientists on the panel. Earlier versions of this same committee included experts from Duke, Harvard and Johns Hopkins, and they turned these peptides down again and again. Congress should set minimum qualifications for FDA advisory panels. The Family Vaccine Protection Act serves as a model: it locks a Centers for Disease Control and Prevention (CDC) vaccine panel's size, required expertise, and meeting schedule into law.
Pass legislation that puts expiration dates on approvals. Once the FDA adds an ingredient to the list pharmacies are allowed to use, the agency has no power to make anyone prove it is safe or that it works. Congress should give every listing a deadline: five years, after which it lapses unless human studies have been submitted, with authority for the agency to demand data before then. While it wouldn’t stop these peptides from getting approved, it would create a ceiling on the damage.
Pass the Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act with a safety-reporting amendment. If these peptides are approved, no one will be required to track what happens next. The bipartisan SAFE Drugs Act would be the first law to make compounding pharmacies—the ones that would actually mix and sell these peptides—report anything to the federal government, albeit only monthly counts of the knockoff drugs they produce. Amend it to require reports of patient injuries as well, and require the FDA to publish them.
Demand congressional oversight. Democrats on the Senate health committee are already investigating how Kennedy remade the CDC’s vaccine advisory panel. But the peptide committee was assembled in a similar way, and no comparable investigation has been announced. Lawmakers can compel the FDA to produce the ethics reviews it says every appointee passed, and explain how six people who sell peptides were cleared to vote on them.
State action:
Pass state safety rules for compounded drugs like peptides. Compounding pharmacies are licensed by states rather than the FDA, so states are the only ones who can police them. California's AB 1990, now moving through the legislature, would require pharmaceutical-grade ingredients, lab testing, record-keeping and honest advertising for compounded weight-loss drugs, with $1,000 in penalties for every dose sold in violation. It was written for Ozempic knockoffs, but the same rules would work for peptides.
Litigation:
Sue over the panel's makeup. The Federal Advisory Committee Act (5 U.S.C. § 1004) requires advisory committees to be "fairly balanced," and a federal judge in Massachusetts (American Academy of Pediatrics v. Kennedy) issued an injunction in March 2026 against RFK's handpicked vaccine panel for likely violating that law—freezing the appointments and wiping out every vote that committee had taken. Fourteen state attorneys general filed a separate suit on the same grounds. A similar argument applies to the peptides case: a panel filled with people who sell the product it was asked to evaluate is not balanced. A court can't order the FDA’s committee to reach a different conclusion, but it can throw out the votes and force the agency to start over with a legitimate panel. Note, though, that the government has appealed the AAP ruling, so the precedent isn't locked in yet.
Challenge the decision under the Administrative Procedure Act, which lets courts throw out agency actions that are "arbitrary and capricious"—exactly what this looks like, considering the FDA abandoned its own scientists' findings without saying why. That case can only be brought once the FDA finalizes a rule based on the panel's advice. First it has to open a public comment period, and individuals and organizations can flood the docket when it does. Public comments preserve the arguments a court would hear later.
Legislation: H.R.3701 - Family Vaccine Protection Act | H.R.6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025 | A.B.1990 - Pharmacy Law (California)
